Pain drugs with safety questions will get advisory committee review
FDA will hold a joint meeting of the Anesthetic and Life Support Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee Jan. 30 to weigh the available safety and efficacy data for all propoxyphene-containing products (including hydrochloric acid, napsylate salts and combination drugs) and decide whether any regulatory action is appropriate. In June 2008, Public Citizen Litigation Group sued FDA for failing to withdraw products containing the painkiller propoxyphene, including AAIPharma's Darvocet (1"The Pink Sheet," July 7, 2008, p. 26)
You may also be interested in...
Public Citizen Litigation Group has had plenty to cheer about this year. It argued four cases before the U.S. Supreme Court, winning three of them. Its one loss was particularly disappointing, though
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Judge ordering permanent injunction against Confidence USA on a complaint filed in 2019 questioned FDA's calculations for requiring the firm to recall and destroy all products it had distributed since February 2018.